Meningiomas: From Pathogenesis to Therapeutics-Current Perspectives and a Holistic Review

Özüm Atasoy

doi:10.17827/aktd.1534133

TR EN

Menenjiyomlar: Patogenezden Tedaviye- Güncel Perspektifler ve Bütünsel Bir İnceleme

Öz

Menenjiyomlar, en sık görülen primer santral sinir sistemi tümörleridir. İyi huylu ve yavaş büyüyen neoplazmlardır. İyi huylu olmalarına rağmen, bulundukları yere bağlı olarak semptomlara ve morbiditeye neden olabilirler. Moleküler belirteçler, 2021 Dünya Sağlık Örgütü'nün MSS tümörleri sınıflandırmasında önem kazanmıştır ve menenjiyomların derecelendirilmesini desteklemek için spesifik moleküler biyobelirteçler önerilmiştir. Cerrahi, histopatolojik tiplendirme ve derecelendirme için doku sağlayan standart tedavidir. Radyoterapi, ameliyat edilemeyen veya tamamen çıkarılamayan menenjiyomlar için bir alternatiftir. Tamamen çıkarılmış grad 1 menenjiyomlar için radyoterapi önerilmezken, 2. veya 3. grad menenjiyomlu hastalar için adjuvan radyoterapi önerilir. Bu derlemede, WHO 2021 sınıflandırma güncellemelerini takiben menenjiyomların epidemiyolojisi, etiyolojisi, risk faktörleri, tedavisi ve radyoterapinin tedavi yaklaşımındaki rolünü inceledik.

Anahtar Kelimeler

radyoterapi , menenjiyom , stereotaktik radyoterapi , radyocerrahi , beyin tümörleri

Meningiomas: From Pathogenesis to Therapeutics-Current Perspectives and a Holistic Review

Abstract

Meningiomas are the most common primary central nervous system tumors. They are benign and slow-growing neoplasms. Although they are benign, they can cause symptoms and morbidity depending on their location. Molecular markers gained importance in the 2021 World Health Organization classification of central nervous system tumors, and specific molecular biomarkers have been suggested to support the grading of meningiomas. Surgery is the standard therapy, providing tissue for histopathological typing and grading. Radiotherapy is an alternative for meningiomas that cannot be operated on or completely resected. Radiotherapy is not recommended for completely resected grade-1 meningiomas, while adjuvant radiotherapy is recommended for patients with grade-2 or grade-3 meningiomas. In this review, we discuss the epidemiology, etiology, risk factors, treatment, and the role of radiotherapy in the treatment approach of meningiomas following the WHO 2021 classification updates.

Keywords

radiotherapy , meningioma , stereotactic radiotherapy , radiosurgery , brain tumors

Kaynakça

1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21:1-100.
2. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E et al. Meningioma. Crit Rev Oncol Hematol. 2008;67:153-71.
3. Bowers DC, Moskowitz CS, Chou JF, Mazewski CM, Neglia JP, Armstrong GT et al. Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2017;35:1570-6.
4. Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol. 2006;80:1-7.
5. Kok JL, Teepen JC, van Leeuwen FE, Tissing WJE, Neggers SJCMM, van der Pal HJ et al. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol. 2019;21:392-403.
6. Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer. 2006;6:152.
7. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002;94:1626-35.
8. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res. 2010;16:4155-64.
9. Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2022;128:47-58.
10. Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM et al. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017;8:109228-237.

11. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-20.
12. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231-51.
13. Smith MJ, O'Sullivan J, Bhaskar SS, Hadfield KD, Poke G, Caird J et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet. 2013;45:295-8.
14. Sahm F, Perry A, Brastianos PK, Santagata S, Claus EB, von Deimling A et al. Meningioma. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer. 2021;284-97.
15. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21:1455-65.
16. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999;85:2046-56.
17. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene. 2011;30:2333-44.
18. Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet. 2004;363:1535-43.
19. Yoneoka Y, Fujii Y, Tanaka R. Growth of incidental meningiomas. Acta Neurochir (Wien). 2000;142:507-11.
20. Gaillard, F., Fahrenhorst-Jones, T. Meningioma. Reference article, Radiopaedia.org. (accessed on 10 July 2022) Available from: https://radiopaedia.org/articles/meningioma.
21. Drape JL, Krause D, Tongio J. MRI of aggressive meningiomas. J Neuroradiol. 1992;19:49-62.
22. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39.
23. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994;80:195-201.
24. Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr, Million RR. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 1988;15:299-304.
25. Mantle RE, Lach B, Delgado MR, Baeesa S, Bélanger G. Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning. J Neurosurg. 1999;91:375-83.
26. Chan MD, Rogers CL, Chaudhuri AA, Flickinger JC, Khuntia D. Benign Brain Tumors: Meningiomas and Vestibular Schwannomas In: Tepper JE.,Foote RL., Michalski JM. Gunderson & Tepper's Clinical Radiation Oncology 5th edition. Elsevier Health Sciences; 2021;508-17.
27. Islim AI, Mohan M, Moon RDC, Srikandarajah N, Mills SJ, Brodbelt AR et al. Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. J Neurooncol. 2019;142:211-21.
28. Zeng L, Liang P, Jiao J, Chen J, Lei T. Will an Asymptomatic Meningioma Grow or Not Grow? A Meta-analysis. J Neurol Surg A Cent Eur Neurosurg. 2015;76:341-7. 29. Lee EJ, Kim JH, Park ES, Kim YH, Lee JK, Hong SH et al. A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. J Neurosurg. 2017;127:971-980.
30. Lee EJ, Park JH, Park ES, Kim JH. "Wait-and-See" Strategies for Newly Diagnosed Intracranial Meningiomas Based on the Risk of Future Observation Failure. World Neurosurg. 2017;107:604-11.
31. Islim AI, Kolamunnage-Dona R, Mohan M, Moon RDC, Crofton A, Haylock BJ et al. A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro Oncol. 2020;22:278-89.
32. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122:4-23.
33. Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys. 1997;39:427-36.
34. Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998;73:936-42.
35. Ganz JC, Backlund EO, Thorsen FA. The results of Gamma Knife surgery of meningiomas, related to size of tumor and dose. Stereotact Funct Neurosurg. 1993;61:23-9.
36. Stafford SL, Pollock BE, Foote RL, Link MJ, Gorman DA, Schomberg PJ et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery. 2001;49:1029-37; discussion 1037-8.
37. Kondziolka D, Flickinger JC, Perez B. Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group. Neurosurgery. 1998;43:405-13; discussion 413-4.
38. DiBiase SJ, Kwok Y, Yovino S, Arena C, Naqvi S, Temple R, Regine WF, Amin P, Guo C, Chin LS. Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. Int J Radiat Oncol Biol Phys. 2004;60:1515-9.
39. Pollock BE, Stafford SL, Utter A, Giannini C, Schreiner SA. Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small- to medium-size meningiomas. Int J Radiat Oncol Biol Phys. 2003;55:1000-5.
40. Pollock BE, Stafford SL, Link MJ, Garces YI, Foote RL. Single-fraction radiosurgery for presumed intracranial meningiomas: efficacy and complications from a 22-year experience. Int J Radiat Oncol Biol Phys. 2012;83:1414-8.
41. Unger KR, Lominska CE, Chanyasulkit J, Randolph-Jackson P, White RL, Aulisi E et al. Risk factors for posttreatment edema in patients treated with stereotactic radiosurgery for meningiomas. Neurosurgery. 2012;70:639-45.
42. Conti A, Pontoriero A, Siddi F, Iatì G, Cardali S, Angileri FF et al. Post-Treatment Edema after Meningioma Radiosurgery is a Predictable Complication. Cureus. 2016;8:e605.
43. Manabe Y, Murai T, Ogino H, Tamura T, Iwabuchi M, Mori Y et al. CyberKnife Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy As First-line Treatments for Imaging-diagnosed Intracranial Meningiomas. Neurol Med Chir (Tokyo). 2017;57:627-33.
44. Simon M, Boström J, Koch P, Schramm J. Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification. J Neurol Neurosurg Psychiatry. 2006;77:767-73.
45. Nabors LB, Portnow J, Baehring J, Bloch O, Brem S, Butowski N et al. Central Nervous System Cancers, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022.
46. Hakim R, Alexander E 3rd, Loeffler JS, Shrieve DC, Wen P, Fallon MP et al. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery. 1998;42:446-53; discussion 453-4.
47. Attia A, Chan MD, Mott RT, Russell GB, Seif D, Daniel Bourland J et al. Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neurooncol. 2012;108:179-85.
48. Hardesty DA, Wolf AB, Brachman DG, McBride HL, Youssef E, Nakaji P et al. The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. J Neurosurg. 2013;119:475-81.
49. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009;64:56-60; discussion 60.
50. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018;129:35-47.
51. Weber DC, Ares C, Villa S, Peerdeman SM, Renard L, Baumert BG et al. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol. 2018;128:260-65.
52. Jenkinson MD, Javadpour M, Haylock BJ, Young B, Gillard H, Vinten J et al. The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials. 2015;16:519.
53. Rogers CL: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma. ClinicalTrials. gov Identifier: NCT03180268. Available from: https://clinicaltrials.gov/ct2/show/NCT03180268?term=NRG+BN+003&draw=2&rank=1.
54. Abacıoğlu MU. Atipik Meningiom Tedavisinde Radyoterapinin Rolü. Türk Nöroşir Derg. 2022;32:90-2.
55. Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol. 1998;37:177-88.
56. DeVries A, Munzenrider JE, Hedley-Whyte T, Hug EB. Die Rolle der Strahlentherapie in der Behandlung maligner Meningiome [The role of radiotherapy in the treatment of malignant meningiomas]. Strahlenther Onkol. 1999;175:62-7.
57. Boskos C, Feuvret L, Noel G, Habrand JL, Pommier P, Alapetite C et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys. 2009;75:399-406.
58. Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM et al. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020;106:790-9.
59. Hasegawa T, Kobayashi T, Kida Y. Tolerance of the optic apparatus in single-fraction irradiation using stereotactic radiosurgery: evaluation in 100 patients with craniopharyngioma. Neurosurgery. 2010;66:688-94; discussion 694-5.
60. Kondziolka D, Levy EI, Niranjan A, Flickinger JC, Lunsford LD. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg. 1999;91:44-50.
61. Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J. Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys. 2007;68:858-63.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Nöroloji ve Nöromüsküler Hastalıklar

Bölüm

Derleme

Yazarlar

Özüm Atasoy ^*
0000-0001-5115-7815
Türkiye

Yayımlanma Tarihi

2 Mart 2026

Gönderilme Tarihi

15 Ağustos 2024

Kabul Tarihi

9 Şubat 2026

Yayımlandığı Sayı

Yıl 2026 Cilt: 35 Sayı: 1

DOI

https://doi.org/10.17827/aktd.1534133

IZ

https://izlik.org/JA58YX36CK

AMA

1.Atasoy Ö. Meningiomas: From Pathogenesis to Therapeutics-Current Perspectives and a Holistic Review. aktd. 2026;35(1):1-9. doi:10.17827/aktd.1534133

Menenjiyomlar: Patogenezden Tedaviye- Güncel Perspektifler ve Bütünsel Bir İnceleme

Öz

Anahtar Kelimeler

Meningiomas: From Pathogenesis to Therapeutics-Current Perspectives and a Holistic Review

Abstract

Keywords

Kaynakça

Ayrıntılar

Birincil Dil

Konular

Bölüm

Yazarlar

Yayımlanma Tarihi

Gönderilme Tarihi

Kabul Tarihi

Yayımlandığı Sayı

DOI

IZ

Kaynak Göster